RSS Feed
Article
6 Drug Stocks Unworthy of Biotech Bull Market
The biotech sector is having a party but not all stocks deserve invites. Here's a list of over-valued or undeserving biotech stocks.
04:37PM 02/07/12
Article
FDA Skeptical of Amgen Drug Ahead of Panel
Amgen's efforts to expand use of its new drug Xgeva met with some resistance from an FDA review posted Monday.
09:13AM 02/06/12
Article
Idenix Falls Casualty to Gilead Hep C Hoopla
Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.
11:13AM 02/03/12
Article
Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance
The star of Gilead's fourth-quarter call was its Hep C drug GS-7977, helping investor overlook lower-than-expected 2012 guidance.
07:48AM 02/03/12
Article
Medivation's Prostate Cancer Drug: Survival Benefit With Low Seizure Risk
Medivation's MDV3100 significantly prolonged survival in prostate cancer patients and seizures -- an investor concern -- doesn't appear to be a problem.
06:05PM 01/31/12
Article
Vertex Wins Early Approval of Cystic Fibrosis Drug
Vertex's Kalydeco is the first therapy to treat an underlying genetic cause of cystic fibrosis.
01:39PM 01/31/12
Article
Biogen's 2012 Forecast Disappoints
Biogen guided to lower-than-expected earnings for 2012.
07:26AM 01/31/12
Article
Vertex Hep C Sales Growth Nears End
Fourth-quarter sales of Vertex's Incivek may hit a high-water mark that will not be equaled as sales level off in 2012.
06:33AM 01/31/12
Article
FDA Approves Roche, Curis Skin-Cancer Drug
Roche and Curis' drug is the first approved therapy for advanced basal cell carcinoma.
11:37AM 01/30/12
Article
Valeant Pulls Ista Pharma Takeout Bid
Citing a lack of progress, Valeant decides not to pursue an all-cash hostile offer for eye drug maker Ista Pharma.
08:22AM 01/30/12
Connect with TheStreet